IMV Inc. Faces Strategic Shift as R&D VP Leaves for BioVaxys – What’s Next?
IMV Inc. faces a pivotal moment after a key R&D executive leaves for BioVaxys, while its immuno‑oncology pipeline stalls and stock value hits a low. Discover what this means for its future strategy.
2 minutes to read